OmniAb, Inc.
About OmniAb, Inc.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $18.7M
- Net income
- -$64.8M
- Total assets
- $300.9M
- Market cap
- $359.5M
- Operating margin
- -369.5%
- Net margin
- -347.0%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $18.7M
- Operating expenses
- $87.6M
- Operating income
- -$69.0M
- Income tax
- -$1.5M
- Net income
- -$64.8M
- EPS (basic)
- $-0.57
- EPS (diluted)
- $-0.57
Balance sheet
- Total assets
- $300.9M
- Current assets
- $65.3M
- Total liabilities
- $33.9M
- Current liabilities
- $16.3M
- Shareholders’ equity
- $267.0M
Cash flow
- Operating cash flow
- -$36.5M
- Investing cash flow
- $6.5M
- Financing cash flow
- $27.9M
- Net cash flow
- -$2.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $359.5M
- EPS (diluted)
- $-0.57
- Shares outstanding
- 157.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 1, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $64.8M in FY2025.
- Revenue declined 68% from FY2022 to FY2025.
- Trading 16% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review OmniAb, Inc..
Write a review
News about OmniAb, Inc.
News & sentiment via Polygon.io
